> Detailanzeige

Ventura-Enríquez, Yanet; Cabello-Gutiérrez, Carlos; Pérez-Calatayud, Ángel Augusto; Cortina-De la Rosa, Evelyn; Fareli-González, Christian Javier; Castillo-Juárez, Paola; Carlos, Alberto Peña-Pérez; Zavaleta-Martínez, Elí Omar; Diaz-Padilla, Elizabeth; Murrieta, Sandra; Álvarez-Jiménez, Violeta Deyanira; Ponce-Medrano, Juan Alberto Díaz; Casillas-Suárez, Catalina; Ocampo-Ocampo, María Angelica; Vargas-De-León, Cruz; Fernández-Sánchez, Verónica

Convalescent Plasma to Treat COVID-19: A Two-Center, Randomized, Double-Blind Clinical Trial

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Convalescent Plasma to Treat COVID-19: A Two-Center, Randomized, Double-Blind Clinical Trial
  • Beteiligte: Ventura-Enríquez, Yanet; Cabello-Gutiérrez, Carlos; Pérez-Calatayud, Ángel Augusto; Cortina-De la Rosa, Evelyn; Fareli-González, Christian Javier; Castillo-Juárez, Paola; Carlos, Alberto Peña-Pérez; Zavaleta-Martínez, Elí Omar; Diaz-Padilla, Elizabeth; Murrieta, Sandra; Álvarez-Jiménez, Violeta Deyanira; Ponce-Medrano, Juan Alberto Díaz; Casillas-Suárez, Catalina; Ocampo-Ocampo, María Angelica; Vargas-De-León, Cruz; Fernández-Sánchez, Verónica
  • Erschienen: MDPI AG, 2022
  • Erschienen in: Life
  • Sprache: Englisch
  • DOI: 10.3390/life12111767
  • ISSN: 2075-1729
  • Schlagwörter: Paleontology ; Space and Planetary Science ; General Biochemistry, Genetics and Molecular Biology ; Ecology, Evolution, Behavior and Systematics
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>Background: The use of convalescent plasma (CP) has been considered for its immunological mechanisms that could benefit patients in moderate and severe stages of COVID-19. This study evaluated the safety and efficacy of the use of donor CP for COVID-19. Material and methods: A double-blind, randomized controlled clinical trial was conducted from May to October 2020. Thirty-nine participants with moderate (II) and severe (III) stages of COVID-19 confirmed by RT-PCR were included. The study randomization rate was set at 3:1. CPs were chosen for application with a neutralizing antibody titer of ≥1:32. Results: We observed a significantly lower 21-day post-transfusion mortality HR: 0.17 (95.0% CI [0.07–0.45, p &lt; 0.001]) in the group receiving CP compared with the control group; protective units (PU) in the group receiving convalescent plasma after seven days were significantly higher (512 (32–16,384) vs. 96 (32–256), p = 0.01); the PAO2/FIO2 index showed a significant improvement in the group receiving CP (251.01 (109.4) vs. 109.2 (62.4), p &lt; 0.001, in the control group). Conclusion: CP is safe and effective, as it decreased mortality in the CP group compared with the control group.</jats:p>
  • Zugangsstatus: Freier Zugang